Use of Trastuzumab Deruxtecan in Ovarian Cancer

EP: 1.Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer

EP: 2.Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer

EP: 3.Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer

EP: 4.Emerging Combinations in Maintenance Therapy for Ovarian Cancer

EP: 5.Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation

Now Viewing

EP: 6.Use of Trastuzumab Deruxtecan in Ovarian Cancer

EP: 7.Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration

EP: 8.Navigating Treatment Strategies for Advanced Cervical Cancer: Localized Therapy, KEYNOTE-A18 Trial Data, and Frontline Approaches

EP: 9.Integrating Tisotumab Vedotin into Ovarian Cancer Therapy

EP: 10.Biomarker Testing in Advanced Endometrial Cancer: Approach, Key Markers, and Impact on Treatment Decisions

EP: 11.Managing Recurrent Endometrial Cancer: Treatment Strategies and RUBY Trial Insights

EP: 12.Durvalumab in Endometrial Cancer: DUO-E Trial Updates

EP: 13.Innovative Combination Strategies for Endometrial Cancer: Updates from LEAP and KEYNOTE-B21 Trials

EP: 14.T-DXd in Advanced Endometrial Cancer

EP: 15.Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

Video content above is prompted by the following:

• Briefly comment on the recent tumor agnostic approval for trastuzumab deruxtecan (T-DXd) based on the findings from DESTINY-PanTumor02.
• Based on available HER2 data in ovarian cancer, what impact will this have on the treatment of advanced ovarian cancer?
• Where do you see T-DXd fitting in your treatment algorithm for ovarian cancer?